Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies.

John SvarenJohn J MoranXingyao WuRiccardo ZuccarinoChelsea BaconYunhong BaiRaghu RameshLaurie GutmannDaniel M AndersonDerek PavelecMichael E Shy

Published in: Annals of neurology (2019)

This platform should be useful in clinical trials for CMT1A as a biomarker of target engagement that can be used to optimize dosing, and the same normalization framework is applicable to other types of CMT. ANN NEUROL 2019;85:887-898.

Keyphrases

clinical trial
single cell
rna seq
cell therapy
high throughput
soft tissue
peripheral nerve
randomized controlled trial
stem cells
phase ii
wound healing
neural network
bone marrow
phase iii